(MedPage Today) — CHICAGO — Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and appeared safe in patients with recurrent glioblastoma (GBM) in a phase I study that also signaled an…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115865
Author :
Publish date : 2025-06-02 20:43:00
Copyright for syndicated content belongs to the linked Source.
